Pulmonary Arterial Hypertension
Conditions
Keywords
pulmonary arterial hypertension, aerobic exercise training, upper extremity, exercise capacity
Brief summary
Decreased exercise capacity, peripheral muscle strength and quality of life and increased dyspnea and fatigue perception is prevalent in patients with pulmonary arterial hypertension. It was demonstrated exercise training has beneficial effects in patients with pulmonary arterial hypertension. However, no study investigated the effects of upper extremity aerobic exercise training, therefore effects of upper extremity aerobic exercise training on outcomes in patients with pulmonary arterial hypertension.
Detailed description
Patients were diagnosed with pulmonary arterial hypertension according to the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of f the European Society of Cardiology (ESC) and European Respiratory Society (ERS). Primary outcome measurement was exercise capacity, secondary outcomes were respiratory and peripheral muscle strength, physical activity, quality of life, fatigue, dyspnea and depression.
Interventions
Training group will receive upper extremity aerobic exercise training using arm ergometer at 50-80% of maximal heart rate and breathing exercises. Training will exercise with arm ergometer 3days/week, for 6 weeks with the assistance of a physiotherapist. Training workload will be undercontrol both using target heart rate and Modified Borg dyspnea scale. Training group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks.
OTHERAlternative upper extremity exercises
Control group will receive alternative upper extremity exercises and breathing exercises. Control group will perform alternative upper extremity exercises 3days/week, for 6 weeks and also breathing exercises 120 times/day, 7 days/week, for 6 weeks. Control group will be followed-up by telephone once a week.
Sponsors
Gazi University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Clinically stable * Under standard medication * Group 1 pulmonary arterial hypertension patients * Having no exacerbation or infection
Exclusion criteria
* Cognitive disorders * Orthopedic and neurological problems * Pneumonia or acute infection * Stage 4 heart failure * Having no comorbidity to avoid performing evaluation and training
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Functional exercise capacity (Oxygen consumption measurement during test) | 6 weeks | Six minute walk test (6MWT) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Peripheral muscle strength | 6 weeks | Hand held dynamometer |
| Pulmonary functions | 6 week | Spirometry |
| Physical activity | 6 weeks | Activity monitor |
| Maximum inspiratory and expiratory muscle strength (MIP, MEP) | 6 weeks | Mouth pressure device |
| Fatigue | 6 weeks | Fatigue Severity Scale (FSS) |
| Generic quality of life | 6 weeks | Short Form (SF-36) Health Survey |
| Depression | 6 weeks | Montgomery Asberg Depression Rating Scale (MADRS) (Turkish versions of all scales) |
| Dyspnea | 6 weeks | Modified Borg and Modified Medical Research Council (MMRC) dyspnea scales |
Countries
Turkey (Türkiye)
Outcome results
None listed